AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00652496
Drug: Bimatoprost 0.02% ophthalmic solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Trial: NCT00652496
Drug: Bimatoprost 0.03% ophthalmic solution
RxNorm normalized name: Bimatoprost 0.03% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
Trial: NCT00187122
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for description of treatment plan.
Trial: NCT00187122
Drug: Daunomycin
RxNorm normalized name: Daunomycin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description section for description of treatment plan.
Trial: NCT00187122
Drug: L-Asparaginase
RxNorm normalized name: L-asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for description of treatment plan.
Trial: NCT00187122
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description section for description of treatment plan.
Trial: NCT00187122
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description section for description of treatment plan.
Trial: NCT00187122
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for description of treatment plan.
Trial: NCT00187122
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description section for description of treatment plan.
Trial: NCT01078376
Drug: Azilsartan medoxomil (TAK-491)
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 80 mg, tablets, orally, one day only
Trial: NCT01078376
Drug: Azilsartan medoxomil (TAK-491)
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
Trial: NCT01078376
Drug: Azilsartan medoxomil (TAK-491)
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
Trial: NCT02843698
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
Trial: NCT01648699
Drug: Osmotic Release Oral System (OROS) hydromorphone
RxNorm normalized name: hydromorphone Extended Release Oral Capsule
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
Trial: NCT01642771
Drug: 5-Fu/epirubicin/CTX following Docetaxel
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
Trial: NCT03023878
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
Trial: NCT03023878
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
Trial: NCT00656578
Drug: 4975
RxNorm normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, solution
Trial: NCT02910726
Drug: indocyanine green (ICG)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02261103
Drug: Pramipexole ER tablets
RxNorm normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02261103
Drug: Pramipexole IR tablets
RxNorm normalized name: pramipexole Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02261103
Drug: Placebo matching Pramipexole ER tablets
RxNorm normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02261103
Drug: Placebo matching Pramipexole IR tablets
RxNorm normalized name: placebo Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05110651
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
Trial: NCT00796497
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
Trial: NCT00794573
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
Trial: NCT00690534
Drug: Insulin Regular
RxNorm normalized name: insulin regular
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: insulin, 0.2 mU/kg/min for 3 hours
Trial: NCT00690534
Drug: L-NMMA
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: variable rate for 3 hours
Trial: NCT00690534
Drug: Sodium Nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: variable rate for 3 hours
Trial: NCT03029689
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
Trial: NCT00986947
Drug: IVIg and rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA).
Trial: NCT02972450
Drug: Vedolizumab 300 MG [Entyvio]
RxNorm normalized name: vedolizumab 300 MG [Entyvio]
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
Trial: NCT02094248
Drug: TPO
RxNorm normalized name: Tpoxx
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection
Trial: NCT02094248
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal saline，1ml/day, s.c injection
Trial: NCT02637466
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01169571
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01294358
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
Trial: NCT03356145
Drug: 12 mL paracervical block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 12 mL of lidocaine
Trial: NCT03356145
Drug: 20 mL paracervical block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 20 mL of lidocaine
Trial: NCT00848640
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg twice daily
Trial: NCT00524693
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg sachets
Trial: NCT01283867
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil 500 mg tablets
Trial: NCT02420938
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
Trial: NCT02420938
Drug: Urelumab
RxNorm normalized name: Urelumab
DrugBank: Urelumab (DB12077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
Trial: NCT04052360
Drug: Cenerimod
RxNorm normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
Trial: NCT03705845
Drug: DeltaGold® Tocotrienol 70%
DrugBank: Tocotrienol (DB12647)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
Trial: NCT00702234
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
Trial: NCT00010803
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg twice a day
Trial: NCT00098540
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01083537
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour
Trial: NCT01083537
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour
Trial: NCT02684942
Drug: Meperidine
RxNorm normalized name: Meperidine
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Trial: NCT02916745
Drug: Porfimer sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
Trial: NCT02335242
Drug: Sildenafil 20 mg tablets
RxNorm normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00690950
Drug: Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg capsule, taken once daily for 12 months
Trial: NCT00089635
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT00984347
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas \[6th delivery and up\] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol
Trial: NCT03353948
Drug: MET
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
Trial: NCT03353948
Drug: COMBI
RxNorm normalized name: Combivir
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
Trial: NCT02135588
Drug: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00266162
Drug: Bosentan administration
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01956864
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
Trial: NCT02453659
Drug: Transdermal Nicotine Patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02007278
Drug: vildagliptin and metformin (combination)
RxNorm normalized name: metformin and linagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
Trial: NCT02007278
Drug: glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02007278
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00365183
Drug: Motexafin gadolinium and pemetrexed
RxNorm normalized name: gadolinium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
Trial: NCT03594045
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
Trial: NCT00795769
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03129295
Drug: MPC-SHRC
RxNorm normalized name: GIVI-MPC
DrugBank: GIVI-MPC (DB17905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet four times a day for 3 days
Trial: NCT00145496
Drug: Asenapine
RxNorm normalized name: Asenapine
DrugBank: Asenapine (DB06216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-10 mg sublingually twice daily for up to 26 weeks
Trial: NCT00145496
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-20 mg by mouth once daily for up to 26 weeks
Trial: NCT03157414
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
Trial: NCT03152474
Drug: Vitamin A 100,000 IU
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed Intramuscular once daily
Trial: NCT04652050
Drug: Tolsura
RxNorm normalized name: Tolsura
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
Trial: NCT02316171
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03321188
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant IV chemotherapy
Trial: NCT03321188
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant IV chemotherapy
Trial: NCT04622202
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral capsule pregabalin 150 mg.
Trial: NCT04622202
Drug: multivitamin
RxNorm normalized name: multivitamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral placebo in the form of oral multivitamin capsule.
Trial: NCT02636803
Drug: oxfendazole
RxNorm normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
Trial: NCT02636803
Drug: albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group receives one 400 mg dose of albendazole
Trial: NCT01505179
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
Trial: NCT00350779
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
Trial: NCT00543634
Drug: Provera 10 mg
RxNorm normalized name: Provera 10 MG Oral Tablet
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of MPA, 4 tablets dissoved in water